Hybrigenics SA Logo

Hybrigenics SA

R&D provider of molecular interaction analysis to accelerate drug discovery for life science sectors.

ALHYG | PA

Overview

Corporate Details

ISIN(s):
FR0004153930
LEI:
9695003KQD0XMJYDX764
Country:
France
Address:
850 BOULEVARD SEBASTIEN BRANT, 67400 ILLKIRCH-GRAFFENSTADEN
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Hybrigenics Services is a specialized R&D solutions provider focused on the discovery and analysis of molecular interactions. With over 25 years of experience, the company offers a suite of proprietary platforms to support clients in the pharmaceutical, biotech, agroscience, and academic sectors. Its core offerings include the ULTImate Y2H™ system for comprehensive protein interaction screening, the YChemH platform for identifying drug-target interactions, and the Hybribody service for custom synthetic nanobody (VHH) selection and validation. Hybrigenics acts as a strategic partner, delivering high-quality, reliable data to accelerate early-stage drug discovery, elucidate mechanisms of action, and advance fundamental scientific research.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-04-30 18:00
Earnings Release
RÉSULTATS ANNUELS CONSOLIDÉS 2024
French 290.7 KB
2024-10-31 18:00
Earnings Release
RÉSULTATS SEMESTRIELS 2024
French 187.0 KB
2024-10-01 18:30
Post-Annual General Meeting Information
Assemblée générale mixte du 30 septembre 2024 : Approbation des comptes annuels…
French 272.4 KB
2024-07-18 18:00
Capital/Financing Update
ATON FINALISE AVEC SUCCES SA RESTRUCTURATION FINANCIERE
French 283.7 KB
2024-06-17 18:30
Pre-Annual General Meeting Information
ASSEMBLEE GENERALE ORDINAIRE LE 2 JUILLET 2024
French 142.5 KB
2024-06-07 18:30
Legal Proceedings Report
ENGAGEMENT DE DISCUSSIONS AVEC LES CREANCIERS EN VUE D'ASSAINIR LA SITUATION FI…
French 148.9 KB
2024-04-30 18:30
Earnings Release
RÉSULTATS ANNUELS 2023 - REPORT DE LA PUBLICATION DU RAPPORT ANNUEL 2023
French 248.9 KB
2024-03-07 18:00
Capital/Financing Update
ÉCHELONNEMENT DU REMBOURSEMENT DE L'EMPRUNT OBLIGATAIRE CONVERTIBLE DE 1,5 M EU…
French 240.5 KB
2024-02-22 18:00
Management Discussion and Analysis
2023 : une année de profondes transformations - Situation de trésorerie au 31 d…
French 282.3 KB
2023-12-22 18:00
Post-Annual General Meeting Information
Compte-rendu de l'assemblée générale du 21 décembre 2023
French 185.9 KB
2023-11-17 18:30
Business and Financial Review
POINT SUR LA SITUATION DU GROUPE ATON (HYBRIGENICS SA)
French 255.7 KB
2023-10-31 18:00
Earnings Release
RESULTATS SEMESTRIELS 2023
French 269.4 KB
2023-10-25 18:00
Capital/Financing Update
ATON (EX-HYBRIGENICS) RENFORCE SES RESSOURCES FINANCIERES EN EMETTANT UN EMPRUN…
French 297.2 KB
2023-10-11 08:00
Regulatory News Service
HYBRIGENICS : Stemcis étend ses horizons à l'international avec l'ouverture d'u…
French 183.5 KB
2023-09-26 17:45
Report Publication Announcement
HYBRIGENICS SE REPOSITIONNE SOUS LE NOM D'ATON ET COMMUNIQUE SA STRATÉGIE POUR …
French 1.4 MB

Automate Your Workflow. Get a real-time feed of all Hybrigenics SA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Hybrigenics SA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Hybrigenics SA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Advancing high-grade copper and precious metal projects from discovery to production.
Canada
COR
Cantargia Logo
Develops antibody treatments targeting IL1RAP for cancer and autoimmune/inflammatory diseases.
Sweden
CANTA
Captor Therapeutics S.A. Logo
Developing TPD therapeutics for oncology and autoimmune diseases with its Optigrade™ platform.
Poland
CTX
Cardiff Oncology, Inc. Logo
Clinical-stage biotech developing a PLK1 inhibitor to treat resistant cancers.
United States of America
CRDF
Cardio Diagnostics Holdings, Inc. Logo
AI-powered epigenetic and genetic tests for early detection of heart disease risk.
United States of America
CDIO
Cardiol Therapeutics Inc. Logo
Develops oral cannabidiol therapies for inflammatory and fibrotic heart diseases.
United States of America
CRDL
CareDx, Inc. Logo
Precision diagnostics and surveillance solutions for the organ transplant journey.
United States of America
CDNA
Offers one-stop BPO, CRM, and staffing for admin, manufacturing, and logistics.
Japan
6070
Caris Life Sciences, Inc. Logo
Pioneering precision cancer care via AI-powered molecular profiling and diagnostics.
United States of America
CAI
Carna Biosciences, Inc. Logo
Develops kinase inhibitor drugs for oncology/autoimmune diseases & offers discovery support services.
Japan
4572

Talk to a Data Expert

Have a question? We'll get back to you promptly.